STAT6 and asthma: Given that ex vivo drug treatment would require a time window for siRNA-mediated suppression to operate [12], in addition to analysing expression of our target gene (STAT6), we also analysed expression of a representative panel of genes linked to both disease (asthma) phenotype and epithelial differentiation status in both nasal models.